The current study was conducted to examine the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy (RT) in women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery (BCS). METH-ODS: Women with DCIS who were treated with BCS and RT from 1980 through 2010 were identified from a prospectively maintained database. IBTR rates, measured from the time of RT completion, were compared between those who initiated RT 8 weeks, >8 to 12 weeks, and >12 weeks after the completion of surgery. The association between RT timing and IBTR was evaluated by Kaplan-Meier and log-rank analyses; Cox modeling was used for multivariable analysis. RESULTS: A total of 1323 women met the inclusion criteria. The median follow-up was 6.6 years, with 311 patients followed for 10 years. A total of 126 IBTR events occurred. Patients were categorized by RT timing: 806 patients (61%) with timing of 8 weeks, 386 patients (29%) with timing of >8 to 12 weeks, and 131 patients (10%) with timing >12 weeks. The 5-year and 10-year IBTR rates were 5.8% and 13.0%, respectively, for RT starting 8 weeks after surgery; 3.8% and 7.6%, respectively, for RT starting >8 to 12 weeks after surgery; and 8.8% and 23.0%, respectively, for an RT delay >12 weeks after surgery (P 5 .004). On multivariable analysis, menopause (hazard ratio [HR], 0.54; P 5 .0009) and endocrine therapy (HR, 0.45; P 5 .002) were found to be protective against IBTR, whereas a delay in RT >12 weeks compared with 8 weeks was associated with a higher risk of IBTR (HR, 1.92; P 5 .014). There was no difference in IBTR noted between RT initiation at 8 weeks and initiation at >8 to 12 weeks after BCS (P 5 .3). CONCLUSIONS: A delay in RT >12 weeks is associated with a significantly higher risk of IBTR in women undergoing BCS for DCIS. Efforts should be made to avoid delays in starting RT to minimize the risk of disease recurrence. Cancer 2018;124:46-54.
INTRODUCTION
Ductal carcinoma in situ (DCIS), or stage 0 breast cancer, is a noninvasive breast lesion that comprises approximately 20% of all breast cancer diagnoses. In 2017, it is estimated that nearly 53,000 women will be diagnosed with DCIS in the United States. 1, 2 The majority of these women (60%-77%) will undergo breast-conserving surgery (BCS), with or without adjuvant therapy. [3] [4] [5] [6] Survival is excellent after BCS for DCIS, with 10-year breast cancer-specific mortality rates of 1% to 4%. [7] [8] [9] [10] However, rates of ipsilateral breast tumor recurrence (IBTR) are not insignificant, with the risk of IBTR reported to be 1% to 3% per year, 5, 8 with long-term recurrence rates reported to range from 25% to 35% after BCS alone in 4 large, prospective, randomized controlled trials. 9, [11] [12] [13] A marked decrease in the risk of IBTR in patients with DCIS has been observed with the use of adjuvant radiotherapy (RT) after BCS. The Early Breast Cancer Trialists' Collaborative Group meta-analysis of 3729 women with DCIS from 4 randomized controlled trials revealed a 10-year relative risk reduction of 54% and a 10-year absolute risk reduction of 15% for IBTR with the addition of RT. 8 Despite the demonstration of a clear benefit for the use of RT in patients with DCIS, to the best of our knowledge, evidence regarding the optimal timing of adjuvant RT is lacking. Of the 4 mature randomized controlled trials, only 2 specified the timing of RT therapy in the protocol: patients enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 and European Organisation for Research and Treatment of Cancer (EORTC) 10853 trials initiated RT within 8 weeks and 12 weeks, respectively, of undergoing BCS. 14, 15 However, it is well documented that in patients with invasive breast cancer, a delay in RT of >8 to 12 weeks leads to an increased risk of IBTR. [16] [17] [18] The objective of the current study was to examine the association between the timing of adjuvant RT and the risk of IBTR in women with DCIS undergoing BCS.
Original Article
MATERIALS AND METHODS
Women were identified from a prospectively maintained database of patients with DCIS undergoing BCS at Memorial Sloan Kettering Cancer Center (MSKCC). Patients were included if they were female, had undergone surgery between 1980 and 2010, and received adjuvant RT. Patients excluded were those with a previous diagnosis of breast cancer, those with synchronous invasive breast cancer, those for whom the RT total dose was unknown or for whom the total RT dose was <4240 centigrays (cGy), and those who were missing the dates of both RT initiation and completion. If the start or end date of RT was not known, it was inferred from the known corresponding end or start date of RT, respectively, using the median duration of RT therapy in the cohort (6 weeks). Of 1323 patients, 53 start dates were inferred from known RT completion dates, and 1 RT end time was inferred from a known start date. Four patients had nonsynchronous bilateral DCIS and were included in the data set as separate entries. The use of these data was approved by the MSKCC Institutional Review Board.
Time to RT was defined as the interval between final definitive surgery (defined as the date of surgery if only one excision was required or the date of final re-excision if multiple procedures were required) and the date of RT initiation. Patients were grouped and analyzed according to the timing of RT initiation (8 weeks, >8-12 weeks, and >12 weeks). Other factors included were age, menopausal status, family history of breast cancer (defined as 1 first-degree or second-degree family members with breast cancer), presentation (radiological or clinical), nuclear grade (low, intermediate, or high), presence of tumor necrosis, number of excisions required (2 or 3), surgical margin status (positive/close [2 mm] or negative [>2 mm]), endocrine therapy, total RT dose, and treatment time period (2000 or 2001) . The number of surgical excisions was included as a surrogate for the size/extent of DCIS.
The primary endpoint was the time interval to first IBTR, calculated from the date of completion of RT to the date of histologically proven disease recurrence. Both biopsy-proven DCIS and invasive breast carcinoma in the ipsilateral treated breast were included as IBTR.
Whole-breast RT was used for all patients, generally prescribed with either the standard schedule of 5000 cGy in 25 treatments or the "hypofractionated" schedule of 4240 cGy in 16 treatments. The additional use of a boost was based on clinical judgment and the final surgical margin status. A sequential boost to the lumpectomy cavity, ranging from 360 cGy to 2160 cGy, was delivered to 81% of patients (1072 patients). For the patients who received RT at an outside institution, treatment summaries documenting the dose and fraction size were obtained and reviewed. Follow-up consisted of annual mammograms, routine interval history, and physical examinations.
Statistical Analysis
Differences in patient characteristics by time to RT initiation were assessed using the chi-square test. The KaplanMeier method was used to estimate 5-year and 10-year recurrence rates in the entire population as well as in each of the time-to-RT cohorts. Hazard ratios (HRs) and Wald test P values for each variable were estimated from univariate and multivariable Cox regression analyses. A multivariable Cox regression model was used to assess the relationship between delay in RT initiation and IBTR while adjusting for patient clinicopathological factors that were found to be associated with IBTR on univariate Cox regression analysis or that varied between RT timing groups. RT dose was modeled as a continuous variable and was rescaled so that the HR corresponded to the effect of a 100-cGy increase in RT dose on the outcome. A sensitivity analysis was performed to ensure that the main finding regarding the relationship between RT timing and IBTR was robust, with the inclusion of 54 patients with inferred start or end dates. All analyses were performed using SAS (version 9.4; SAS Institute Inc, Cary, North Carolina) and R (version 3.1.1; R Foundation, Vienna, Austria) statistical software. All statistical tests were 2-sided, and a P value <.05 was considered statistically significant.
RESULTS
Of 3001 patients with DCIS who were treated with BCS, 1596 patients underwent RT and 1323 patients had known RT initiation or completion dates with an RT dose 4240 cGy (Fig. 1) . The median patient age was 56 years (range, 27-86 years). The median follow-up was 6.6 years (range, 0-30.7 years), with 311 women followed for at least 10 years. Of the 126 IBTR events, 56% were DCIS recurrences and 44% were invasive carcinomas. The overall cumulative incidence of IBTR at 5 years and 10 years was 5.5% and 12.5%, respectively ( Fig. 2A) .
Differences in Patient, Tumor, and Treatment Characteristics by RT Cohort
RT was initiated within 8 weeks of surgery in 806 patients (61%), whereas 386 patients (29%) began RT between 8 and 12 weeks after surgery, and 131 patients (10%) experienced a delay in RT after surgery of >12 weeks. The median delay in the group in whom RT was initiated >12 weeks after definitive surgery was 14.1 weeks (range, 12.1-62.4 weeks). Patient, tumor, and treatment characteristics are listed in Table 1 . Compared with the cohorts who had a longer time interval to RT, the cohort of women who initiated RT within 8 weeks had a nonsignificantly higher percentage of premenopausal/perimenopausal women (40% vs 35% and 33%, respectively; P 5.10) and a nonsignificant difference in the use of endocrine therapy between groups, with less frequent use found among women who experienced a delay in RT (28% vs 25% and 19%, respectively; P 5 .07). DCIS with necrosis significantly varied between groups (78% vs 73% and 71%, respectively; P 5.05). The RT dose varied by time to RT (P<.0001), with mean RT doses of 5778 cGy (median, 6000 cGy), 5665cGy (median, 6000 cGy), and 5595cGy (median, 5980 cGy), respectively, in patients who initiated RT within 8 weeks, between 8 and 12 weeks after surgery, and >12 weeks after surgery. Patient age, family history of breast cancer, presentation, nuclear grade, number of surgical excisions, surgical margin status, and year of surgery did not appear to vary significantly between RT timing cohorts. The incidence of IBTR varied significantly by time to initiation of RT (P<.005) (Fig. 2B) . Five-year IBTR rates for patients initiating RT within 8 weeks, between 8 to 12 weeks, and at >12 weeks were 5.8%, 3.8%, and 8.8%, respectively. The 10-year IBTR rates for patients who initiated RT within 8 weeks, between 8 to 12 weeks, and at >12 weeks were 13.0%, 7.6%, and 23.0%, respectively (Table 2) .
On univariate regression analysis, a delay in RT initiation of >12 weeks was found to be associated with a were similar to those based on the full sample of 1323 patients. The log-rank test for the full sample comparing IBTR by RT timing groups was 0.0042, and the log-rank test for the sample without the 54 patients with inferred dates demonstrated a P of .0015.
Multivariable Model for IBTR
On multivariable analysis, after adjustment for clinicopathologic and treatment factors found to be significantly associated with IBTR on univariate analysis (menopausal status, clinical vs radiologic presentation, use of endocrine therapy) as well as factors that varied between RT timing groups (menopausal status, necrosis, endocrine therapy, RT dose), delay in RT initiation remained a significant risk factor for IBTR (overall P<.02) ( 
DISCUSSION
In this population of patients with DCIS who were undergoing BCS with adjuvant RT, we observed higher IBTR rates among those who experienced a delay in the initiation of RT after surgical excision, with a risk of IBTR in women who initiated RT >12 weeks after surgery that was 1.9 times greater than that of patients who initiated RT within 8 weeks of surgery. This relationship persisted after adjusting for other variables correlated with time to RT or associated with IBTR in this population. The overall 10-year IBTR rates for patients receiving RT within 8 weeks and between 8 to 12 weeks after surgery were 13.0% and 7.6%, respectively, which align with previous studies delineating an IBTR rate of approximately 1% per year in patients with DCIS who undergo BCS and RT. 5, 8, 10, 19 Conversely, the 10-year recurrence rate for patients in whom RT was delayed >12 weeks was 23.0%, which is nearly double that expected based on previous studies. It is interesting to note that IBTR rates in the cohort of patients who initiated RT >12 weeks after definitive surgery mirrors those noted among patients with DCIS treated at the study institution with BCS without adjuvant treatment. 20 This suggests a smaller benefit from the initiation of RT beyond 12 weeks after surgery.
Although the literature demonstrates that positive surgical margins are associated with a higher risk of IBTR, 8, 12, 21, 22 we previously demonstrated that positive or close surgical margins were not associated with IBTR in this population of women receiving adjuvant RT after undergoing BCS for DCIS (P 5.95). 19 The results of the current study reiterate these findings with the addition of RT timing in the analysis. It is likely that the observed lack of effect of positive/close surgical margins on IBTR in this population is due to the fact that few women had positive surgical margins. Furthermore, the majority of "positive" or close surgical margins were only focally positive rather than across a broad front, and most were positive or close at the fascia or the dermis rather than at a radial margin. Therefore, the patients in the current study with positive/close surgical margins most likely had a lower residual disease burden compared with some other studied populations. In addition to the known clinicopathologic and treatment factors associated with an increased risk of IBTR among women with DCIS, such as premenopausal status and lack of adjuvant endocrine therapy, a delay in RT initiation of >12 weeks appears to be associated with worse outcomes. The findings of the current study are similar to those of numerous studies demonstrating an increased risk of IBTR with an RT delay of >8 to 12 weeks after surgery for invasive breast cancer. [16] [17] [18] In a meta-analysis by Huang et al examining 7401 patients with breast cancer, those patients who initiated RT between 9 to 16 weeks after undergoing BCS had a 62% increased risk of local disease recurrence at 5 years compared with patients who initiated RT within 8 weeks; however, the analysis was limited because use of chemotherapy was not analyzed as a possible confounding variable. 16 Similarly, using the Quebec Tumor Registry, Hebert-Croteau et al studied 1062 patients with stage I to stage II breast cancer with negative lymph nodes undergoing BCS with RT. With a mean follow-up of 7.1 years and while controlling for multiple clinicopathologic factors such as age, comorbidity, adjuvant systemic therapies, and surgical margins, this study found a 75% increased risk of local recurrence in women who initiated RT >12 weeks after surgery compared with those who initiated RT within 8 weeks. 18 Delay in RT also has been shown to be associated with breast cancer-specific survival among patients with invasive breast cancer. In a Surveillance, Epidemiology, and End Results (SEER)-based study of 13,907 women aged >65 years with stage I to stage II invasive breast cancer undergoing BCS with RT, Hershman et al found close to a 4-fold increased risk of diseasespecific mortality for women who initiated RT >12 weeks after surgery compared with patients who received RT within 12 weeks. 23 The reason for an association between RT delay and IBTR is likely complex and multifactorial. Retrospective series have highlighted several variables associated with a delay in RT that also may impact IBTR risk. Madubata et al examined the relationship between time to RT initiation and race among 9138 women diagnosed with DCIS between 1996 and 2011 in the Missouri Cancer Registry. Although there was no difference in rates of RT use noted by race, black women experienced significant delays in the initiation of RT after BCS (8.1 weeks vs 6.3 weeks in white women; odds ratio, 1.9 [P<.0001]). 24 In addition to a delay in RT, black women also experienced an increased risk of IBTR, although a causal relationship could not be determined. 24 Race also may affect the risk of disease-specific mortality in women with DCIS. In a SEER-based review of 108,196 women, Narod et al examined breast cancerspecific mortality in patients with first primary DCIS. With a median follow-up of 7.5 years, the results of their study demonstrated that black women had a 2.4-fold increased risk of death after a diagnosis of stage 0 breast cancer compared with white non-Hispanic women (P<.001), whereas other patient ethnicities included in the analysis (white Hispanic, Asian, and other) were not found to have a significantly increased risk. 7 However, this retrospective study did not examine the association between race and the use of or delay in adjuvant therapies.
Other factors also may affect both outcomes and timing to RT. In a study of nearly 25,000 women with invasive breast cancer, >13,000 of whom underwent BCS with adjuvant RT, a longer time to RT initiation was found to be associated with older age, advanced stage of disease, being unmarried, and increased comorbidities, in addition to black race. 23 Warren et al used a 2-year SEER sample of 1103 women with DCIS, 7% of whom had a Charlson Comorbidity Index of 1, and found a 62% increased risk of IBTR with the presence of patient comorbidities compared with patients without comorbidities. 25 In a study of 1026 women with DCIS by Gold et al, patients with a higher comorbidity burden experienced 1.8 times increased odds of experiencing an RT delay of >8 weeks compared with those without the presence of comorbidities. 26 Lack of data regarding race and comorbidities in the current study cohort is a limitation, because these factors may influence the timely receipt of RT and IBTR.
Another possibility is that the association between delay in RT initiation and increased risk of IBTR may be related to a biologic difference in the effectiveness of RT at different time points. If the effect of RT after surgery is time-dependent secondary to the inflammatory state and acute changes in the tissue microenvironment postoperatively, then one would expect a difference in therapeutic effectiveness with RT delay.
The major strengths of the current study are the large study population and prospectively recorded data with long-term follow-up. Although the follow-up for this cohort went as long as 30 years, with 311 patients being followed for at least 10 years, additional long-term follow-up is indicated for a disease process with a longterm risk of recurrence. These findings should be generalizable to other populations given that previous MSKCC studies 20 using the same database have reported prognoses and outcomes that closely match those of other American, European, and Asian populations. [27] [28] [29] [30] [31] Furthermore, these data have the advantage of being robust clinical data compared with population-based databases that use coded data. However, the current study is subject to the same limitations as all retrospective analyses, including the inability to determine causality versus association.
Conclusions
A delay in the initiation of RT of >12 weeks after BCS among women with DCIS is associated with a significantly higher risk of IBTR. Future research should aim to understand the reasons for RT delays and to explore whether the relationship between RT delay and IBTR is causal or simply associative. Although confounding factors may underlie this relationship, until a causal relationship can be excluded, efforts should be made to avoid delays in the initiation of RT to minimize risk of disease recurrence.
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